Duloxetine Capsule, Delayed Release
Product Images NDC 71205-602

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71205-602). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-602-90 (Duloxetine 30mg)

Label for Duloxetine 30 mg delayed-release capsules by Proficient Rx LP. Contains 60 capsules per bottle. The label includes dosing details, product ID QD060260, and manufacturing info noting Ajanta Pharma USA Inc. as marketer and product made in India. It also provides storage instructions and multiple NDC codes 71205-602-60.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve showing the proportion of patients with relapse over time (days) from randomization, comparing treatment with Duloxetine versus placebo. The x-axis represents time from randomization to relapse in days, and the y-axis represents the proportion of patients with relapse. The Duloxetine group shows a lower proportion of relapse over time compared to placebo.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The graph shows higher patient improvement percentages for Duloxetine across different pain improvement thresholds.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time for Duloxetine versus placebo. The x-axis represents time from randomization to relapse in days, ranging from 0 to 300. The y-axis shows the proportion of patients with relapse, from 0.0 to 1.0. The graph includes two lines: a dashed line for placebo and a solid line for Duloxetine, showing lower relapse proportions for Duloxetine over time.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at different dosages (60 mg BID, 60 mg QD, 20 mg QD) and placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved, with four distinct lines representing each treatment group.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups, indicating varying levels of pain improvement among these groups.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph showing percent improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups, illustrating the relationship between dosage and pain improvement over a range of percentages.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Duloxetine groups show higher improvement percentages compared to placebo.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing percentage of patients improved based on percent improvement in pain from baseline, showing two data series: placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved, with both series declining as pain improvement percentage increases.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved between placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved. Duloxetine consistently shows higher patient improvement across pain reduction percentages.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of Duloxetine hydrochloride depicting the molecular arrangement including a naphthalene group, thiophene ring, and an amine group attached to a chiral center.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.